Test Xpert ® MTB/RIF et dépistage des nouveaux cas de tuberculose pulmonaire en routine dans une zone de haute endémicité tuberculeuse

Horo, K.; N’Guessan, R.; Koffi, Mathurin; Kouamé-N’Takpé, N.; Koné, A.; Samaké, K.; Koffi, L.; Ahui, B.J.M.; Brou-Gode, C.V.; N’gom, A.; Kouassi, B.; Koffi, N.; Aka-Danguy, É.

doi:10.1016/j.rmr.2016.10.874

Cited by 5 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We excluded it because of concern about duplicate data. In addition, the criteria for the reference standard for rifampicin resistance detection were not satisfiedFong 2017AbstractFriedrich 2011aThis study evaluated Xpert MTB/RIF for the diagnosis of pleural TBGama de Andrade 2017AbstractGelalcha 2017Includes both adults and children or no information about age of enrolmentGounder 2014Includes both adults and children or no information about age of enrolmentGriesel 2016AbstractGriesel 2017Includes data for pulmonary and extrapulmonary TB combinedGuenaoui 2016Includes both adults and children or no information about age of enrolmentGupta 2014AbstractGurbanova 2016AbstractGurbanova 2017Includes data for pulmonary and extrapulmonary TB combinedGursoy 2016Includes both adults and children or no information about age of enrolmentHabeenzu 2017Includes both adults and children or no information about age of enrolmentHanifa 2016Reference standard not satisfiedHeidebrecht 2016Data insufficient for 2 x 2 tableHillemann 2011This study evaluated Xpert MTB/RIF for the diagnosis of extrapulmonary TBHiza 2017Not a diagnostic accuracy studyHo 2016Community‐based screeningHoro 2017Includes both adults and children or no information about age of enrolmentHu 2014Includes both adults and children or no information about age of enrolmentHuang 2018Includes both adults and children or no information about age of enrolmentHuerga 2017Xpert was not the index testIoannidis 2010We could not obtain this article…”

Section: Characteristics Of Excluded Studies [Ordered By Study Id]mentioning

confidence: 99%

Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults

Horne

Kohli

Zifodya

et al. 2019

Cochrane Database of Systematic Reviews

187

157

View full text Add to dashboard Cite

Background Xpert MTB/RIF (Xpert MTB/RIF) and Xpert MTB/RIF Ultra (Xpert Ultra), the newest version, are the only World Health Organization (WHO)‐recommended rapid tests that simultaneously detect tuberculosis and rifampicin resistance in persons with signs and symptoms of tuberculosis, at lower health system levels. A previous Cochrane Review found Xpert MTB/RIF sensitive and specific for tuberculosis ( ). Since the previous review, new studies have been published. We performed a review update for an upcoming WHO policy review. Objectives To determine diagnostic accuracy of Xpert MTB/RIF and Xpert Ultra for tuberculosis in adults with presumptive pulmonary tuberculosis (PTB) and for rifampicin resistance in adults with presumptive rifampicin‐resistant tuberculosis. Search methods We searched the Cochrane Infectious Diseases Group Specialized Register, MEDLINE, Embase, Science Citation Index, Web of Science, Latin American Caribbean Health Sciences Literature, Scopus, the WHO International Clinical Trials Registry Platform, the International Standard Randomized Controlled Trial Number Registry, and ProQuest, to 11 October 2018, without language restriction. Selection criteria Randomized trials, cross‐sectional, and cohort studies using respiratory specimens that evaluated Xpert MTB/RIF, Xpert Ultra, or both against the reference standard, culture for tuberculosis and culture‐based drug susceptibility testing or MTBDR plus for rifampicin resistance. Data collection and analysis Four review authors independently extracted data using a standardized form. When possible, we also extracted data by smear and HIV status. We assessed study quality using QUADAS‐2 and performed meta‐analyses to estimate pooled sensitivity and specificity separately for tuberculosis and rifampicin resistance. We investigated potential sources of heterogeneity. Most analyses used a bivariate random‐effects model. For tuberculosis detection, we first estimated accuracy using all included studies and then only the subset of studies where participants were unselected, i.e. not selected based on prior microscopy testing. Main results We identified in total 95 studies (77 new studies since the previous review): 86 studies (42,091 participants) evaluated Xpert MTB/RIF for tuberculosis and 57 studies (8287 participants) for rifampicin resistance. One study compared Xpert MTB/RIF and Xpert Ultra on the same participant specimen. Tuberculosis detection Of the total 86 studies, 45 took place in high tuberculosis burden and 50 in high TB/HIV burden countries. Most studies had low risk of bias. Xpert MTB/RIF pooled sensitivity and specificity (95% credible Interval (CrI)) were 85% (82% to 88%) and 98% (97% to 98%), (70 studies, 37,237 unselected participants; high‐certainty evidence). We found similar accuracy when ...

show abstract

Section: Characteristics Of Excluded Studies [Ordered By Study Id]mentioning

confidence: 99%

Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults

Horne

Kohli

Zifodya

et al. 2019

Cochrane Database of Systematic Reviews

187

157

View full text Add to dashboard Cite

show abstract

“…Microscopic examination after ZN staining remains the most accessible and least expensive examination in semi-urban areas, with a more or less acceptable sensitivity [12]. Compared to the result of Horo et al [18] who found a sensitivity of 85% with respect to the reference test, which is the culture. The variability of its diagnostic performance is related to the quality of the samples, the bacillary richness of the sputum, the dye used and the experience of the reader.…”

Section: Microscopy and Xpert Mtb/rif ® Testingmentioning

confidence: 99%

Contribution of XPERT MTB/RIF® in the diagnosis of pulmonary tuberculosis in Ziguinchor, Senegal

Sarr

Niang

Dieye

et al. 2020

Microbes and Infectious Diseases

View full text Add to dashboard Cite

Background: Multidrug-resistant tuberculosis (MDR-TB) is resistant to isoniazid and rifampicin. It is favored by poverty and infection with the human immunodeficiency virus. This retrospective, descriptive study aimed to determine the contribution of Xpert MTB/RIF® in the diagnosis of multidrug-resistant pulmonary tuberculosis in a semiurban environment at the Peace Hospital of Ziguinchor in Senegal during the period from April 2015 to August 2019. Methods: The study is retrospective, descriptive and carried out in the laboratory of Ziguinchor Hospital de la Paix, in southern Senegal, from April 2015 to August 2019. All respiratory specimens were subjected to Ziehl-Neelsen (ZN) stained smear microscopy and Xpert MTB/RIF® testing. Results: 180 samples, i.e. 6.4% were microscopy-negative but positive in Xpert MTB/RIF ® testing. Thirty_two (32) patients (1%) are infected with rifampicin-resistant Mycobacterium tuberculosis (M. tuberculosis), against 29% of patients (798/2794) infected with susceptible strains. Conclusion: Tuberculosis is no longer a "disease of the past". Having a high cost, Xpert MTB/RIF ® testing must be associated with microscopy, which remains accessible in semiurban areas and easy to perform.

show abstract

Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis

Zifodya

Kreniske

Schiller

et al. 2021

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Test Xpert ® MTB/RIF et dépistage des nouveaux cas de tuberculose pulmonaire en routine dans une zone de haute endémicité tuberculeuse

Cited by 5 publications

References 18 publications

Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults

Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults

Contribution of XPERT MTB/RIF® in the diagnosis of pulmonary tuberculosis in Ziguinchor, Senegal

Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis

Contact Info

Product

Resources

About